AKBA News Alert Akebia Therapeutics Inc. (AKBA) 11.03 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Akebia Therapeutics Inc. (AKBA) 11.03 $AKBA

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), FPRX: 21.92 (+0.07), ZFGN: 21.67 (-0.08), CRIS: 1.15 (-0.01), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Akebia Therapeutics, Inc. Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 6:50AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on Monday, December 22, 2014.
AKBA: 11.03 (+0.44)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 30.02 (+0.70), ZSPH: 44.19 (-2.83), AMRN: 1.03 (-0.02), OPHT: 45.94 (+0.36), AERI: 28.04 (-1.08), ASPX: 25.09 (+0.78), CNCE: 10.58 (+0.11), ICEL: 5.41 (+0.14), GWPH: 67.64 (-0.49), AUXL: 32.75 (-0.01), RTRX: 11.12 (+0.56), RCPT: 114.46 (-0.67), AAVL: 50.79 (-0.48), AKBA: 11.03 (+0.44), EXPR: 13.63 (+0.04), RARE: 40.65 (+0.89), ZGNX: 1.11 (-0.03), RLYP: 31.59 (-1.40), PETX: 11.88 (-0.71), ENTA: 41.14 (-1.97), RDUS: 26.30 (+1.20), CARA: 9.54 (-0.19), FLML: 16.48 (+0.27), ALIM: 5.47 (+0.13), ANIP: 55.08 (+1.32), ICPT: 129.30 (-4.61), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10), NDAQ: 45.74 (-0.72), FPRX: 21.92 (+0.07), CRIS: 1.15 (-0.01), ZFGN: 21.67 (-0.08), QLTI: 3.41 (-0.03), PCYC: 129.56 (+1.12), PTX: 9.20 (+0.06), CLDN: 17.76 (+0.03), RIGL: 2.12 (+0.01), HPTX: 21.60 (-0.06), AMPH: 11.28 (+0.25), INO: 8.34 (+0.08), VSAR: 19.17 (+0.11), FMI: 20.73 (-0.15), TBPH: 13.48 (-0.13), XLRN: 37.63 (-0.37), MGNX: 28.79 (-0.20), INSM: 13.70 (-0.13), ONTX: 3.94 (-0.12), ALDR: 24.79 (-0.77), SAGE: 37.66 (+3.29), KITE: 52.49 (-1.41), CGEN: 7.98 (-0.01), FOLD: 7.73 (-0.15), KPTI: 31.07 (-0.82)

Akebia to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Thu Dec 04, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on Thursday, December 11,2014 at 1:00 p.m. Eastern Time. The conference will take place at Crowne Plaza Times Square Manhattan in New York City.
AKBA: 11.03 (+0.44)

Akebia Therapeutics President and Chief Executive Officer Establishes Stock Purchase Plan
Business Wire - Mon Nov 17, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), announced today that John P. Butler, President and Chief Executive Officer of Akebia, has established a personal stock purchasing plan to acquire shares of the company's common stock. The purchasing plan complies with Section 10b5-1 of the Securities Exchange Act of 1934, as amended, which enables securities holders to adopt pre-arranged stock purchasing plans for the acquisition of predetermined amounts of securities on a non-discretionary basis.
AKBA: 11.03 (+0.44)

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
CLUB: 5.91 (-0.09), HYGS: 11.82 (-0.28), KNDI: 10.52 (-1.06), MCEP: 6.16 (+0.66), HYG.TO: 13.99 (-0.36), RPRX: 8.21 (+0.13), SHLD: 30.87 (-0.27), PAA.TO: 10.37 (-0.16), PAAS: 8.91 (-0.12), REXX: 5.19 (+0.60), AKBA: 11.03 (+0.44), GCBC: 29.01 (-0.68), ASEI: 48.93 (+1.85), MTEX: 29.26 (-0.14), PLNR: 6.60 (-0.16)

Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Business Wire - Tue Nov 11, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
AKBA: 11.03 (+0.44)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 10.29 (-0.16), JRJC: 5.70 (-0.88), NAVB: 1.50 (-0.05), SANW: 3.68 (+0.16), PLPM: 1.93 (+0.07), RYN: 25.91 (-0.19), INFU: 2.75 (+0.03), LIOX: 5.46 (-0.05), DY: 30.80 (-0.16), MTZ: 18.87 (+0.19), CGIX: 6.29 (+0.12), MUX: 0.93 (-0.05), OREX: 5.91 (-0.09), URRE: 1.92 (-0.03), ACHN: 12.92 (+0.20), REN: 1.03 (-0.01), MPO: 1.42 (+0.26), AKBA: 11.03 (+0.44), TRX: 0.60 (-0.11), PLNR: 6.60 (-0.16)

Akebia misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:20AM CST

AKBA: 11.03 (+0.44)

Akebia Announces Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
AKBA: 11.03 (+0.44)

Akebia to Participate in Upcoming Investor Conferences
Business Wire - Fri Oct 31, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:
AKBA: 11.03 (+0.44)

Akebia getting roughed up
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:55PM CDT

AKBA: 11.03 (+0.44)

Akebia renal anemia drug successful in Phase 2
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 6:13AM CDT

AKBA: 11.03 (+0.44)

Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
Business Wire - Mon Oct 27, 5:30AM CDT
--Company Plans to Initiate Global Phase 3 Registration Studies in 2015
AKBA: 11.03 (+0.44)

Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
Business Wire - Thu Sep 25, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. AKB-6548 is being developed as a once-daily, oral therapy with best-in-class potential for the treatment of anemia related to CKD.
AKBA: 11.03 (+0.44)

Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:57AM CDT
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 26% on the day.
LCI: 42.70 (-1.35), AKBA: 11.03 (+0.44), CNCE: 10.58 (+0.11), HPTX: 21.60 (-0.06)

Others Overlooked Akebia Therapeutics (AKBA), Should You Buy It Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:45AM CDT
Akebia Therapeutics has been witnessing a positive trend in its current year estimates and possess a favorable Zacks Rank #2(Buy)
AKBA: 11.03 (+0.44)

Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors
Business Wire - Mon Sep 15, 6:15AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that Ronald C. Renaud, Jr., former President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc., has been appointed to Akebia's Board of Directors.
AKBA: 11.03 (+0.44), IDIX: 24.50 (+0.05)

Akebia Therapeutics, Inc. (NASDAQ: AKBA) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Thu Sep 11, 9:06AM CDT
What:
AKBA: 11.03 (+0.44), NDAQ: 45.74 (-0.72)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 173

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 123

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 203

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

dbt Labs Transforms Data Management with MetricFlow Open Source

Updated Category News Views 735

Embracing Open Source with MetricFlow In a groundbreaking move, dbt Labs recently announced its commitment to advancing trustworthy AI by open sourcing MetricFlow. This initiative represents a significant turning point in how organizations manage and utilize data in the era of artificial intelligence. The shift to an Apache 2.0 license not only safeguards the integrity of...

Continue Reading
EssilorLuxottica Achieves Euro 2 Billion Bond Issuance Success

Updated Category News Views 117

EssilorLuxottica's Successful Bond Issuance EssilorLuxottica has reached a noteworthy milestone by successfully issuing a Euro 2 billion bond at an attractive average rate of 2.99%. This strategic financial move highlights the company's strong position in the market and its appeal to investors. Details of the Bond Issuance The bond issuance features tenors of 4.5 years...

Continue Reading
Streamlined Home Selling Solutions Introduced in North Carolina

Updated Category News Views 292

Revolutionizing Home Selling in North Carolina Fair Cash Offers For Homes has recently launched its innovative service, ‘Sell Your House Fast North Carolina,’ designed to facilitate quick and efficient sales for homeowners. With the ever-changing real estate landscape, many individuals find themselves needing to sell their properties under various circumstances,...

Continue Reading
Ipsen Employee Admits to Insider Trading on Cancer Drug Deal

Updated Category News Views 268

Guilty Plea Tied to a Drugmaker’s Takeover Plans An employee at the French pharmaceutical company Ipsen has agreed to plead guilty to insider trading. The case, centered on trading ahead of a proposed acquisition, underscores the stakes around confidentiality in drug development and the pressures that test corporate governance. What Prosecutors Allege Dishant Gupta,...

Continue Reading
Oscar Health Achieves 52-Week Record with $23.45 Stock Price

Updated Category News Views 221

Oscar Health Achieves New Stock Performance Highs In a striking example of market resilience, Oscar Health, Inc. (OSCR) has reached an impressive 52-week high with its stock hitting $23.45. This achievement signifies a remarkable growth phase for the company, which has experienced an incredible one-year change of 288.51%. Investors have shown strong support for Oscar...

Continue Reading